Molecular and phosphoproteomic characterisation of FLT3 inhibitor resistance in acute myeloid leukaemia

- Staudt Barreto, Dilana Elisabeth

Identifying novel therapeutic targets for the treatment of Acute Myeloid Leukaemia

- Murray, Heather

Targeting Oncogenic Signaling in Mutant FLT3 Acute Myeloid Leukemia: The Path to Least Resistance

- Staudt, Dilana, Murray, Heather C., McLachlan, Tabitha, Alvaro, Frank, Enjeti, Anoop K., Verrills, Nicole M., Dun, Matthew D.

Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors

- Smith, Amanda M., Dun, Matthew D., Toop, Hamish, Lock, Richard B., Powell, Jason A., Thomas, Daniel, Guthridge, Mark A., Moore, Andrew, Ashman, Leonie K., Skelding, Kathryn A., Enjeti, Anoop, Verrills, Nicole M., Lee, Erwin M., Harrison, Celeste, Kahl, Richard, Flanagan, Hayley, Panicker, Nikita, Mashkani, Baratali, Don, Anthony S., Morris, Jonathan

FMS-like tyrosine kinase 3 (FLT3) inhibitors: molecular docking and experimental studies

- Mashkani, Baratali, Tanipour, Mohammad Hossein, Saadatmandzadeh, Mohammad, Ashman, Leonie K., Griffith, Renate

Differences in growth promotion, drug response and intracellular protein trafficking of FLT3 mutants

- Mashkani, Baratali, Griffith, Renate, Ashman, Leonie

Targeting PP2A activation as a novel therapeutic strategy for receptor tyrosine kinase driven leukaemia

- Smith, Amanda Melanie

MicroRNA-16 is down-regulated in mutated FLT3 expressing murine myeloid FDC-P1 cells and interacts with Pim-1

- Kim, Kyu-Tae, Carroll, Adam P., Mashkani, Baratali, Cairns, Murray J., Small, Donald, Scott, Rodney J.